Medicare AdvantagePrior AuthMedium impact
Amzeeq® (minocycline) Topical Foam (Revised)
Humana·Dermatology, Family Medicine, Internal Medicine·Medicare Advantage
We identified it
Jul 21, 2026
Summary
Humana has issued a revised Prior Authorization policy for Amzeeq® (minocycline) Topical Foam affecting Medicare Advantage members. This is a 1-day-old policy update that supersedes any previous guidance on this medication. Billing teams must immediately implement prior authorization requirements for this topical acne treatment to avoid claim denials.
Action Required
Immediately: Billing team and providers must implement prior authorization requirement for Amzeeq® (minocycline) Topical Foam before submitting claims to Humana Medicare Advantage plans. (1) Update billing system to flag all Amzeeq prescriptions for prior auth review; (2) Notify dermatology and primary care providers that this medication now requires pre-approval; (3) Add prior auth requirement to encounter templates and superbill forms; (4) Contact Humana at the source URL (https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a584806) to obtain specific PA submission procedures, clinical criteria, and turnaround times. Claims submitted without prior authorization will be denied for Humana Medicare Advantage members.